Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H23NO.ClH |
| Molecular Weight | 281.821 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2
InChI
InChIKey=ZBUVYROEHQQAKL-UHFFFAOYSA-N
InChI=1S/C16H23NO.ClH/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17;/h6-9,14H,3-5,10-12H2,1-2H3;1H
| Molecular Formula | C16H23NO |
| Molecular Weight | 245.3599 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://pharmacybook.net/mydocalm/ | http://en.remedy-info.com/ovr0_midokalm.html | https://www.ncbi.nlm.nih.gov/pubmed/18482024 | https://www.ncbi.nlm.nih.gov/pubmed/232053
Curator's Comment: description was created based on several sources, including
https://pharmacybook.net/mydocalm/ | http://en.remedy-info.com/ovr0_midokalm.html | https://www.ncbi.nlm.nih.gov/pubmed/18482024 | https://www.ncbi.nlm.nih.gov/pubmed/232053
Tolperisone is a centrally acting muscle relaxant first synthesized in 1956 and used in clinical practice since the 1960’s. Tolperisone is an aryl alkyl β-aminoketone with an asymmetric carbon atom α to the carbonyl group. The dextrorotatory enantiomer was reported less effective, however, no detailed analyses of the enantiomers are available. The precise mechanism of action of tolperisone is not fully known. The most prominent effect of tolperisone is its inhibitory action on pathways of spinal reflexes. It suppresses the mono and polysynaptic reflex transmission by both pre-synaptic and post-synaptic mechanisms.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Convulsive mechanism of ketamine anesthesia]. | 1975 Aug |
|
| [Neuropharmacological studies on tolperisone hydrochloride (author's transl)]. | 1979 Oct |
|
| Simultaneous determination of tolperisone and lidocaine by high performance liquid chromatography. | 2001 Dec |
|
| Use of vancomycin silica stationary phase in packed capillary electrochromatography I. Enantiomer separation of basic compounds. | 2001 Feb |
|
| [Spastic syndrome. More mobile again after stroke]. | 2001 Mar 8 |
|
| [Mydeton: a centrally acting muscle relaxant drug from Gedeon Richter LTD]. | 2002 |
|
| [Fibromyalgia problem case. Monotherapy is mostly insufficient]. | 2002 Apr 25 |
|
| [Patient with chronic backache. Disabled or muscle spasm patient?]. | 2002 Dec 5 |
|
| Protein domain of chicken alpha(1)-acid glycoprotein is responsible for chiral recognition. | 2002 Jul 19 |
|
| [Preventing chronification. So pain isn't branded into memory]. | 2002 May 16 |
|
| [Muscular pain and fatigue: is fibromyalgia sticking behind? These points bring it to light]. | 2002 Oct 31 |
|
| [Mydocalm causing anaphylaxis]. | 2003 |
|
| Effect of muscle relaxants on experimental jaw-muscle pain and jaw-stretch reflexes: a double-blind and placebo-controlled trial. | 2003 |
|
| Prophylactic tolperisone for post-exercise muscle soreness causes reduced isometric force--a double-blind randomized crossover control study. | 2003 |
|
| Separation of basic drug enantiomers by capillary electrophoresis using chicken alpha1-acid glycoprotein: insight into chiral recognition mechanism. | 2003 Aug |
|
| [To make easier everyday life of stroke patients. Muscle relaxants diminish spasms]. | 2003 Feb 27 |
|
| Anaphylactic reactions to tolperisone (Mydocalm). | 2003 Jun 28 |
|
| Simultaneous micellar LC determination of lidocaine and tolperisone. | 2003 Mar 26 |
|
| Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. | 2003 May |
|
| [Fibromyalgia also has psychological origins. "Often harmony seeking perfectionists"]. | 2003 May 1 |
|
| Antinociceptive effects of sodium channel-blocking agents on acute pain in mice. | 2004 Jun |
|
| [A study of mydocalm efficiency in the treatment of chronic headache of tension]. | 2005 |
|
| [Midocalm in complex therapy of chronic low back pain syndrome]. | 2005 |
|
| Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. | 2005 Dec |
|
| A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. | 2005 Jun |
|
| Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. | 2005 Sep-Oct |
|
| [Post-operative pain therapy of a chronic pain patient]. | 2006 Nov |
|
| [Use of local injections of tolperisone (midocalm) in combination with tractional therapy in the treatment of vertebral static syndrome]. | 2007 |
|
| Grand rounds: an outbreak of toxic hepatitis among industrial waste disposal workers. | 2007 Jan |
|
| Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. | 2008 Summer |
|
| [Co-analgesics--today and tomorrow--a receptor-based overview of therapeutical options]. | 2009 Nov |
|
| [New therapies for spastic movement disorders]. | 2009 Oct |
|
| [IGOST guideline for pharmacotherapy of low back pain]. | 2010 Aug 12 |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
| Classification of drugs based on properties of sodium channel inhibition: a comparative automated patch-clamp study. | 2010 Dec 20 |
|
| Differential effects of painful and non-painful stimulation on tactile processing in fibromyalgia syndrome and subjects with masochistic behaviour. | 2010 Dec 28 |
|
| Tolperisone. | 2010 Feb |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Sample Use Guides
In Vivo Use Guide
Sources: https://pharmacybook.net/mydocalm/
The usual dose is Mydocalm (tolperisone) 150 mg, 1-3 times a day. It should be taken after meal. The maximum daily dose is 450 mg
Route of Administration:
Oral
The sodium channel blocking effects of Tolperisone was characterized in electrophysiological experiments on dorsal root ganglion (DRG) cells. DRG cells were acutely dissociated from rat DRG of 6-day-old male rats. Tolperisone (0, 40, 80, 160, 320, and 640 mkM) dissolved in the extracellular solution were applied onto the cells via multibarreled ejection pipettes controlled by electromagnetic valves. Currents were recorded from fast-kinetics tetrodotoxin-sensitive DRG cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:57:39 GMT 2023
by
admin
on
Fri Dec 15 14:57:39 GMT 2023
|
| Record UNII |
8Z075K2TIG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3644-61-9
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY | |||
|
100000084637
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY | |||
|
SUB04912MIG
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY | |||
|
222-876-5
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY | |||
|
C84220
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY | |||
|
8Z075K2TIG
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY | |||
|
92965
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY | |||
|
DTXSID2045868
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY | |||
|
DBSALT002004
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY | |||
|
m10951
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1076211
Created by
admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |